Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Turns To M&As To Meet Goal Of Replacing Expiring Drugs

This article was originally published in PharmAsia News

Executive Summary

Takeda Pharmaceutical plans to acquire some companies and merge with others this year in an effort to beef up its oncology drug pipeline and stave off the impact of expiring patents. Takeda faces a problem in having two promising drugs delayed in development and marketing approval as it faces expirations on other key drugs. Takeda sees patent expiration as its "year 2010 problem" and has been counting on having replacements ready for at least two of its best-selling drugs, Prevacid (lansoprazole) for treating ulcers and Actos (pioglitazone) for diabetes, but each has faced a delay at U.S. FDA. To meet a plan to increase sales by 30 percent in fiscal 2010, Takeda now must look at cancer-fighting drugs of other makers. (Click here for more - a subscription may be required

You may also be interested in...



Takeda Readying To Launch PPI Kapidex Within A Month

TOKYO - Takeda expects to launch within a month its Kapidex (dexlansoprazole) delayed- release capsules for the treatment of gastroesophageal reflux disease, the same proton pump inhibitor class of drugs as its Prevacid, which is scheduled to lose patent protection this year, according to the company's third-quarter earnings call Feb. 3

FDA Says GMP Lapses In Facilities And Production Areas More Common For Cell And Gene Therapies

US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.

Anti-BCMA Therapies Aim To Raise The Bar In Myeloma

GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.

UsernamePublicRestriction

Register

LL1128174

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel